Abstracts tagged "Myositis"

Abstract Number: 2085 • ACR Convergence 2024
The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study
Brittany Adler¹, Michael Bene¹, Cissy Zhang², Julie Paik¹, Christopher Mecoli¹, Thomas Lloyd³, Eleni Tiniakou⁴, Erika Darrah¹, Lisa Christopher-Stine¹, Albert Mears¹, Megan McGowan¹, Ruben Pagkatipunan¹, Anne Le² and Jemima Albayda⁵, ¹Johns Hopkins University, Baltimore, MD, ²Gigantest, Baltimore, MD, ³Baylor College of Medicine, Houston, TX, ⁴Johns Hopkins University, Lutherville Timonium, MD, ⁵Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disease for which there is no effective treatment. Mitochondrial dysregulation is a pathologic hallmark of IBM.…
Abstract Number: 0323 • ACR Convergence 2024
Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies
Didem Saygin¹, Anne-Marie Malfait², Kristin Wipfler³, Christopher G McKennan⁴, Jiaxuan Duan⁴, Kaleb Michaud⁵ and Yvonne Lee⁶, ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Division of Rheumatology, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Pittsburgh, Department of Statistics, Pittsburgh, PA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Northwestern University, Chicago, IL
Background/Purpose: The cardinal symptom of idiopathic inflammatory myopathies (IIM) is muscle weakness leading to functional limitations in the majority of the patients. With a shift…
Abstract Number: 0348 • ACR Convergence 2024
Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies
Ting Zhang¹, Qiyuan Wang², Wenjia Sun³, Lei Liu¹ and Jing Xue⁴, ¹Zhejiang University, Hangzhou, China (People's Republic), ²Zhejiang Univerisity, Hangzhou, China (People's Republic), ³The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China (People's Republic), ⁴The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in idiopathic inflammatory myopathies (IIM), substantially contributing to the morbidity and mortality. ILD…
Abstract Number: 1153 • ACR Convergence 2024
Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Vasiliki Koulouri¹, Ilektra Voulgareli², Sofia Flouda³, Nikoletta Galanopoulou⁴, Nikolaos Marketos⁵, Charalampos Skarlis⁵, Sylvia Raftopoulou⁵, Kyriaki Tavernaraki⁶, Alexia Chronaiou², Georgios Tsoukalas², Nikolaos Zias⁷, Dimitrios Boumpas⁸ and Clio Mavragani⁹, ¹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ²4th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ³4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, ⁴10th Respiratory Medicine Department, Sotiria General and Chest Diseases Hospital, Athens, Greece, ⁵Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁶Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, Athens, Greece, ⁷Respiratory Medicine Department, Athens Naval Hospital, Athens, Greece, ⁸4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece, ⁹Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: In recent years, connective tissue diseases (CTDs) have been increasingly recognized as a significant underlying pathology of interstitial lung diseases (ILDs). Amongst CTDs, idiopathic…
Abstract Number: 1275 • ACR Convergence 2024
Implementing Integrated Mental Health Care in a Juvenile Myositis Clinic: A One-Year Review
Luana Flores Pereira¹, Louise Boulard², Kayla M. Baker³, Audrey Bell-Peter⁴, Vanessa Carbone³, Brian Feldman⁵, Jayne MacMahon⁶, Valerio Maniscalco⁷, Jo-Anne Marcuz⁸, Tanya Slater⁴, Kristi Whitney⁴, Y. Ingrid Goh³ and Andrea Knight⁹, ¹Neurosciences and Mental Health Program, SickKids Research Institute, Toronto, ON, Canada, ²Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto; Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada, ⁷Rheumatology Unit, ERN-ReCONNET Center, Meyer Children Hospital IRCCS; Department of Pediatrics, Santo Stefano Hospital, Florence, Italy, ⁸Division on Rheumatology, The Hospital for Sick Children; Department of Rehabilitation Services, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Juvenile myositis (JM) patients experience a high burden of emotional distress, yet mental health (MH) care is not typically integrated into standard clinical practices.…
Abstract Number: 2068 • ACR Convergence 2024
Poloxamers 188 & 182 Are Effective in Repairing the Membrane Resealing Defect in Myositis
Shane Bruckner¹, Braden Zeno², Gianni Giarrano³, Alexis Tucker³, Hannah Bulgart⁴, Brian Paleo³, Kassidy Banford³, Nicholas Young⁴, Rohit Aggarwal⁵, Chester Oddis⁶, Paula Clemens⁷, Dana Ascherman⁸, Noah Weisleder¹ and Wael Jarjour⁹, ¹Ohio State University, Columbus, OH, ²Ohio State, Upper Arlington, OH, ³Ohio State University, Columbus, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Pittsburgh, Pittsburgh, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
Abstract Number: 2086 • ACR Convergence 2024
Specific Transcriptomic Profile Associated with Disease Activity in Muscle Biopsies from Patients with Sarcoid Myopathy
Iago Pinal-Fernandez¹, Nikolas Ruffer², Maria Casal-Dominguez³, katherine Pak⁴, Stefania Dell'Orso⁵, Faiza Naz⁵, Shamima Islam⁶, Gusatavo Gutierrez-Cruz⁶, Margherita Milone⁷, Albert selva-O'Callaghan⁸, jose milisenda⁹, Felix Kleefeld¹⁰, Andrew Mammen⁶, Teerin Liewluck¹¹ and Werner Stenzel¹², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²Klinikum Bad Bramstedt, Hamburg, Germany, ³NIAMS, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁶NIH, Bethesda, MD, ⁷Mayo Clinic-Rochester, Rochester, MN, ⁸Systemic Autoimmune Disease Section, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁹Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁰Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany, Berlin, Germany, ¹¹Mayo Clinic, Rochester, MN, ¹²Charite University, Berlin, Germany
Background/Purpose: Sarcoidosis, a multisystem inflammatory disorder of unknown etiology, exhibits diverse clinical manifestations, with symptomatic musculoskeletal involvement being relatively uncommon but potentially debilitating. We conducted…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 0642 • ACR Convergence 2024
Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus
Eugene Krustev¹, Marvin Fritzler², Sasha Bernatsky³, Yvan St-Pierre⁴, Evelyne Vinet⁵, Christian Pineau⁶, Arielle Mendel⁷, Faras Kalache⁸, Louis-Pierre Grenier⁸, Thaisa Cotton⁸, Omid Zahedi⁹ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²Mitogen Diagnostics Corp, Calgary, AB, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Medicine, McGill University and Centre for Outcomes Research and Evaluation, McGill University Health Centre, Montreal, QC, Canada, ⁸Division of Rheumatology, Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
Background/Purpose: Although autoimmune myositis (AIM) and interstitial lung disease (ILD) are uncommon in systemic lupus erythematosus (SLE), they are associated with worse outcomes. Myxovirus Resistance…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 1575 • ACR Convergence 2024
Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis
Kevin Chevalier¹, Guillaume Chassagnon², Sarah LOUIS-LEONARD³, Pascal cohen⁴, bertrand Dunogue⁵, Alexis Régent⁶, Benjamin Thoreau⁵, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of Radiology, Hôpital Cochin, AP-HP. Centre Université Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France, Paris, France, ³Sorbonne Université, INSERM, Department of Neurormyologie and Neuropathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic disease within the connective tissue disease (CTD) spectrum. It is characterized by microcirculatory abnormalities, skin and internal…
Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Lovely Kumari¹, VISHNU KONERU², subin Philip¹, sai Kumar Dunga³, Mamatha gorijavulu⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Molly Thabah⁷, Vir Singh Negi⁸ and Chengappa Kavadichanda⁹, ¹JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ²JIPMER,PUDUCHERRY, PUDUCHERRY, India, ³JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, ⁴JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶JIPMER, Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁸AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, ⁹Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
Abstract Number: 2305 • ACR Convergence 2024
Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Marie ROBERT¹, Yann Nguyen², Yurdagül Uzunhan³, Benjamin Terrier⁴, Yves Allenbach⁵, Alain Meyer⁶, Jacques-Eric Gottenberg⁷, JEROME HADJADJ⁸, Zahir Amoura⁹, ARNAUD HOT¹⁰, Eléonore Bettacchioli¹¹, Elisabeth Aslangul¹², Rakiba Belkhir¹³, Frederic Desmoulins¹⁴, Elisabeth Bergé¹⁴, Pascale Chrétien¹⁵, Pascale Roland-Nicaise¹⁶, Claire Goulvestre¹⁷, Jean-Luc Charuel¹⁸, Benoit Nespola¹⁹, Nicole Fabien²⁰, Eric Ballot²¹, Gaetane Nocturne¹⁴, Xavier Mariette¹⁴, Samuel Bitoun¹ and Raphaele Seror²², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Service de Médecine interne et immunologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ⁹French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, ¹⁰Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ¹¹Service de Rhumatologie, CHU de Brest, Brest, France, ¹²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ¹³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ¹⁴Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁵Laboratoire d'immunologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, France, ¹⁶Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France, ¹⁷Laboratoire d'immunologie, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ¹⁸Laboratoire d'immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France, ¹⁹Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²⁰Laboratoire d'immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, ²¹Laboratoire d'immunologie, Hôpital Saint-Antoine, AP-HP, Paris, Ile-de-France, France, ²²Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease characterized by a wide range of symptoms, and 30% to 60% of patients developed systemic manifestations. The…
Abstract Number: 0325 • ACR Convergence 2024
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Jerapas Thongpiya¹, Pojsakorn Danpanichkul¹ and Yanint Raksadawan³, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].